Novartis Pharmaceuticals Canada has announced that the Québec provincial government will now provide reimbursement for the TOBI Podhaler tobramycin DPI for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.The company cites data from Cystic Fibrosis Canada that show about 1,200 cystic fibrosis patients residing in Québec.
TOBI Podhaler received market authorization in Canada in April 2011 and launched in the UK in September. The dry powder inhaler is disposable and is replaced on a weekly basis in order to reduce the risk of contamination.
Read the Novartis Pharmaceuticals Canada press release.
